1 octgt research suzanne epstein, ph.d. associate director for research, octgt 12-14-2010
TRANSCRIPT
![Page 1: 1 OCTGT Research Suzanne Epstein, Ph.D. Associate Director for Research, OCTGT 12-14-2010](https://reader036.vdocuments.site/reader036/viewer/2022062718/56649e675503460f94b62cf5/html5/thumbnails/1.jpg)
1
OCTGT Research
Suzanne Epstein, Ph.D.
Associate Director for Research, OCTGT
12-14-2010
![Page 2: 1 OCTGT Research Suzanne Epstein, Ph.D. Associate Director for Research, OCTGT 12-14-2010](https://reader036.vdocuments.site/reader036/viewer/2022062718/56649e675503460f94b62cf5/html5/thumbnails/2.jpg)
2
OCTGT Mission
Facilitate development of, approval of, and access to safe and effective CTGT products
![Page 3: 1 OCTGT Research Suzanne Epstein, Ph.D. Associate Director for Research, OCTGT 12-14-2010](https://reader036.vdocuments.site/reader036/viewer/2022062718/56649e675503460f94b62cf5/html5/thumbnails/3.jpg)
3
Products Regulated by OCTGT
Cellular therapies Tumor vaccines and immunotherapy Gene therapies Tissue and tissue-based products Xenotransplantation products Combination products Devices used for cells/tissues Cord blood
![Page 4: 1 OCTGT Research Suzanne Epstein, Ph.D. Associate Director for Research, OCTGT 12-14-2010](https://reader036.vdocuments.site/reader036/viewer/2022062718/56649e675503460f94b62cf5/html5/thumbnails/4.jpg)
4
CBER Office of Cellular, Tissue, and Gene Therapies
Office of the DirectorCelia M.Witten, Ph.D., M.D., Director
Stephanie Simek, Ph.D. Deputy DirectorSuzanne Epstein, Ph.D. Associate Director of Research
Richard McFarland, M.D., Ph.D., Associate Director of Policy
Division of Cellular and Gene TherapiesRaj Puri, M.D., Ph.D., Director
Kimberly Benton, Ph.D., Deputy Director
Division of Human TissuesEllen Lazarus, M.D., Director
Division of Clinical Evaluation and Pharmacology/ToxicologyVacant
Wilson Bryan, M.D., Clinical Branch ChiefMercedes Serabian, MS., Pharm/Tox Branch Chief
![Page 5: 1 OCTGT Research Suzanne Epstein, Ph.D. Associate Director for Research, OCTGT 12-14-2010](https://reader036.vdocuments.site/reader036/viewer/2022062718/56649e675503460f94b62cf5/html5/thumbnails/5.jpg)
5
OCTGT regulatory portfolio and activities
Over 1350 active INDs and IDEs, over 4500 INDamendments in 2009, plus consult reviews Two licensed products, a growing number of IND products
in advanced development Devices: 510ks, PMAs, HDEs Tissue regulations Pre-INDs, pre-pre-IND advice Policy and guidance, advisory committee meetings Inspections, regulatory site visits Enforcement actions, international activities
![Page 6: 1 OCTGT Research Suzanne Epstein, Ph.D. Associate Director for Research, OCTGT 12-14-2010](https://reader036.vdocuments.site/reader036/viewer/2022062718/56649e675503460f94b62cf5/html5/thumbnails/6.jpg)
6
Guidance Examples
Potency testing for cell and gene therapies
Therapeutic cancer vaccines
Allogeneic pancreatic islet cell products
Cell therapy for cardiac disease
Cord Blood
Good Tissue Practices
International Harmonization on Genomic Biomarkers
![Page 7: 1 OCTGT Research Suzanne Epstein, Ph.D. Associate Director for Research, OCTGT 12-14-2010](https://reader036.vdocuments.site/reader036/viewer/2022062718/56649e675503460f94b62cf5/html5/thumbnails/7.jpg)
7
Additional DCGT regulatory portfolio and activities
Partnerships: National Toxicology Program, NIH, CDC, NCI/IOTF program, NIH stem cell task force, NIST, MATES, TERMIS, ASTM
Participation in international conference on harmonization (ICH), WHO
Outreach talks at conferences, academic institutions, consumer and patient advocacy group meetings
Liaison activities with professional groups Publication of manuscripts on regulatory topics
![Page 8: 1 OCTGT Research Suzanne Epstein, Ph.D. Associate Director for Research, OCTGT 12-14-2010](https://reader036.vdocuments.site/reader036/viewer/2022062718/56649e675503460f94b62cf5/html5/thumbnails/8.jpg)
8
OCTGT research: Stay ahead of the curve as
products and technologies evolve
For this wide spectrum, cannot have research related to each product.
If research addressed only the products and assays of today, we would already be obsolete. We must guide pre-IND work, prepare the way for anticipated products.
![Page 9: 1 OCTGT Research Suzanne Epstein, Ph.D. Associate Director for Research, OCTGT 12-14-2010](https://reader036.vdocuments.site/reader036/viewer/2022062718/56649e675503460f94b62cf5/html5/thumbnails/9.jpg)
9
OCTGT research: Stay ahead of the curve as
products and technologies evolve
For this wide spectrum, cannot have research related to each product.
If research addressed only the products and assays of today, we would already be obsolete. We must guide pre-IND work, prepare the way for anticipated products.
![Page 10: 1 OCTGT Research Suzanne Epstein, Ph.D. Associate Director for Research, OCTGT 12-14-2010](https://reader036.vdocuments.site/reader036/viewer/2022062718/56649e675503460f94b62cf5/html5/thumbnails/10.jpg)
10
Research Strategy in OCTGT
OCTGT products are diverse and rapidly evolving. They use new regulatory paradigms, developing rather than established
Fill scientific gaps, deal with barriers Perform studies relevant to entire product classes
(sponsors study individual products) Make results public, and thus accessible to all sponsors,
to advance the entire field Perform horizon scanning to choose prioritiesScientific areas emphasized will be covered in the Division
Director summary
![Page 11: 1 OCTGT Research Suzanne Epstein, Ph.D. Associate Director for Research, OCTGT 12-14-2010](https://reader036.vdocuments.site/reader036/viewer/2022062718/56649e675503460f94b62cf5/html5/thumbnails/11.jpg)
11
Roles of researcher-reviewer PIs
Regulatory: product/CMC review (IND, 510k, IDE, BLA), policy and guidance
development, pre-application consultation, regulatory outreach, inspections,
mentoring, advisory committee preparation, enforcement, international activities
Administrative: branch chief duties, emergency preparedness, CBER coordinating
committees, research management
Research: including lab management, training/mentoring
Grant writing: increasing role of competitive resources
Peer review: manuscripts, grant applications, PCE
Participation in the scientific community: scientific talks, chairing conference sessions,
editing
![Page 12: 1 OCTGT Research Suzanne Epstein, Ph.D. Associate Director for Research, OCTGT 12-14-2010](https://reader036.vdocuments.site/reader036/viewer/2022062718/56649e675503460f94b62cf5/html5/thumbnails/12.jpg)
12
Investigator recruitment
Scientific gap identified with input from staff, field of expertise endorsed by Center Director's office
Open, public recruitment with search committee.
PI recruitments in DCGT in recent years:
Field: Investigator recruited from:
Organ development Jackson Lab. Proteomics Univ. of Kansas Retrovirology Louisiana State University Tissue safety Armed Forces Institute of Pathology Immunity and tolerance Scripps Research Institute Ongoing: iPS cells ?
![Page 13: 1 OCTGT Research Suzanne Epstein, Ph.D. Associate Director for Research, OCTGT 12-14-2010](https://reader036.vdocuments.site/reader036/viewer/2022062718/56649e675503460f94b62cf5/html5/thumbnails/13.jpg)
13
OCTGT Research Management
Announcement of regulatory/public health goals PI annual reports address research goals and progress,
describe periodic refocusing/adjustment Analysis of productivity and alignment with OCTGT goals Horizon scanning for gaps, to guide recruitment Increasing role of targeted intramural funding allocated by
peer review of proposals Tracking of outside resources Communication tools: work in progress seminars, annual
report summaries. CBER expertise database being developed.
![Page 14: 1 OCTGT Research Suzanne Epstein, Ph.D. Associate Director for Research, OCTGT 12-14-2010](https://reader036.vdocuments.site/reader036/viewer/2022062718/56649e675503460f94b62cf5/html5/thumbnails/14.jpg)
14
2009 OCTGT Research Priorities(responsive to CBER priorities)
1. Chemistry, manufacturing, controls: Development and evaluation of methods and standards for improved product characterization and lot release testing, including definition of product markers predictive of safe, effective, and consistent product performance.
2. Pharmacology, toxicology, product rationale: Development and evaluation of preclinical/nonclinical in vitro and in vivo methods and studies informative about the safety and efficacy of OCTGT products.
3. Participation in CBER-, FDA-, and DHHS-wide initiatives including risk assessment, clinical trial design and monitoring, development of markers, counterterrorism, pandemic influenza preparedness, and HIV/AIDS programs, as well as OCTGT-specific initiatives in these areas.
4. Improvement of the microbial safety of human tissue products by development and evaluation of methods for better processing conditions, pathogen inactivation, and/or pathogen detection.
![Page 15: 1 OCTGT Research Suzanne Epstein, Ph.D. Associate Director for Research, OCTGT 12-14-2010](https://reader036.vdocuments.site/reader036/viewer/2022062718/56649e675503460f94b62cf5/html5/thumbnails/15.jpg)
15
Thank you to the site visitors
for reviewing CBER research programs
and providing your insights.